Effects of selective modulation of the central melanocortin-3-receptor on food intake and hypothalamic POMC expression

Peptides

Volumn 29, Issue 3, 2008, Pages 440-447

  Lee, Michelle ^a   Kim, Andrea ^a   Conwell, Irene M ^a   Hruby, Victor ^b   Mayorov, Alexander ^b   Cai, Minying ^b   Wardlaw, Sharon L ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b University of Arizona   (United States)

Author keywords

Feeding; Melanocortin 3 receptor; MSH; POMC

Indexed keywords

GAMMA INTERMEDIN; HORMONE RECEPTOR BLOCKING AGENT; KETAMINE; MELANOCORTIN 3 RECEPTOR; PG 932; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG; XYLAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; FOOD INTAKE; HYPOTHALAMUS; IN VITRO STUDY; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RAT;

ANIMALS; EATING; GAMMA-MSH; HYPOTHALAMUS; MALE; PRO-OPIOMELANOCORTIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MELANOCORTIN, TYPE 3;

RATTUS;

EID: 39649094099     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.11.005     Document Type: Article

References (34)

1. Abbott C.R., Rossi M., Kim M.S., AlAhmed S.H., Taylor G.M., Ghatei M.A., et al. Investigation of the melanocyte stimulating hormones on food intake: lack of evidence to support a role for the melanocortin-3-receptor. Brain Res 869 (2000) 203-210
2. Bagnol D., Lu X.Y., Kaelin C.B., Day H.E., Ollmann M., Gantz I., et al. Anatomy of an endogenous antagonist: relationship between agouti-related protein and proopiomelanocortin in brain. J Neurosci 19 (1999) 1-7
3. Blum M., Roberts J.L., and Wardlaw S. Androgen regulation of proopiomelanocortin gene expression and peptide content in the basal hypothalamus. Endocrinology 124 (1989) 2283-2288
4. Bouret S., Prevot V., Croix D., Jegou S., Vaudry H., Stefano G.B., et al. Mu-opioid receptor mRNA expression in proopiomelanocortin neurons of the rat arcuate nucleus. Brain Res Mol Brain Res 70 (1999) 155-158
5. Butler A.A., Kesterson R.A., Khong K., Cullen M.J., Pelleymounter M.A., Dekoning J., et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141 (2000) 3518-3521
6. Butler A.A. The melanocortin system and energy balance. Peptides 27 (2006) 281-290
7. Castro M.G., and Morrison E. Post-translational processing of proopiomelanocortin in the pituitary and in the brain. Crit Rev Neurobiol 11 (1997) 35-57
8. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X., Yu H., et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 26 (2000) 97-102
9. Chen A.S., Metzger J.M., Trumbauer M.E., Guan X.M., Frazier E.G., Marsh D.J., et al. Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 9 (2006) 145-154
10. Chhajlani V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol Biol Int 38 (1996) 73-80
11. Cowley M.A., Smart J.L., Rubinstein M., Cerdan M.G., Diano S., Horvath T.L., et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 411 (2001) 480-484
12. Danielson P.E., Forss-Petter S., Brow M.A., Calavetta L., Douglass J., Milner R.J., et al. p1B15: a cDNA clone of the rat mRNA encoding cyclophilin. DNA 7 (1988) 261-267
13. Emeson R.B., and Eipper B.A. Characterization of pro-ACTH/endorphin-derived peptides in rat hypothalamus. J Neurosci 6 (1986) 837-849
14. Grieco P., Balse-Srinivasan P., Han G., Weinberg D., MacNeil T., Van der Ploeg L.H., et al. Extensive structure-activity studies of lactam derivatives of MT-II and SHU-9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. J Pept Res 62 (2003) 199-206
15. Grieco P., Balse P.M., Weinberg D., MacNeil T., and Hruby V.J. d-Amino acid scan of gamma-melanocyte-stimulating hormone: importance of Trp(8) on human mc3 receptor selectivity. J Med Chem 43 (2000) 4998-5002
16. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., et al. Targeted disruption of the melanocortin-receptor results in obesity in mice. Cell 88 (1997) 131-141
17. Jaffe S.B., Sobieszcztk S., and Wardlaw S.L. Effect of opioid antagonism on beta-endorphin processing and proopiomelanocortin-peptide release in the hypothalamus. Brain Res 648 (1994) 24-31
18. Jegou S., Boutelet I., and Vaudry H. Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. J Neuroendocrinol 12 (2000) 501-505
19. Kelly M.J., Loose M.D., and Ronnekleiv O.K. Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance. Neuroendocrinology 52 (1990) 268-275
20. Kim M.S., Rossi M., Abbot C., AlAhmed S.H., Smith D.M., and Bloom S.R. Sustained orexigenic effect of agouti related protein may be not mediated by the melanocortin 4 receptor. Peptides 23 (2002) 1069-1076
21. f) rats. Endocrinology 141 (2000) 2465-2471
22. Korner J., Wissig S., Kim A., Conwell I.M., and Wardlaw S.L. Effects of agouti-related protein on metabolism and hypothalamic neuropeptide gene expression. J Neuroendocrinol 15 (2003) 1116-1121
23. Krude H., Biebermann H., Luck W., Horn R., Brabant G., and Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in human. Nat Genet 19 (1998) 155-157
24. Markowitz C.E., Berkowitz K.M., Jaffe S.B., and Wardlaw S.L. Effect of opioid receptor antagonism on proopiomelanocortin peptide levels and gene expression in the hypothalamus. Mol Cell Neurosci 3 (1992) 184-190
25. Marks D.L., Butler A.A., Turner R., Brookhart G., and Cone R.D. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 144 (2003) 1513-1523
26. Marks D.L., and Cone R.D. The role of the melanocortin-3 receptor in cachexia. Ann NY Acad Sci 994 (2003) 258-266
27. Marks D.L., Hruby V., Brookhart G., and Cone R.D. The regulation of food intake by selective stimulation of the type 3 melanocortin receptor (MC3R). Peptides 27 (2006) 259-264
28. Marks D.L., Ling N., and Cone R.D. Role of the central melanocortin system in cachexia. Cancer Res 61 (2001) 1432-1438
29. Marsh D.J., Hollopeter G., Huszar D., Laufer R., Yagaloff K.A., Fisher S.L., et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 21 (1999) 119-121
30. Schiöth H.B., Bouifrouri A.A., Rudzish R., Muceniece R., Watanobe H., Wikberg J.E., et al. Pharmacological comparison of rat and human melanocortin 3 and 4 receptors in vitro. Regul Pept 106 (2002) 7-12
31. Smith A.I., and Funder J.W. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev 9 (1988) 159-179
32. Wardlaw S. Obesity as a neuroendocrine disease: lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab 86 (2000) 1442-1446
33. Yaswen L., Diehl N., Brennan M.B., and Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5 (1999) 1066-1070
34. Zhang Y., Kilroy G.E., Henagan T.M., Prpic-Uhing V., Richards W.G., Bannon A.W., et al. Targeted deletion of melanocortin receptor subtypes 3 and 4, but not CART, alters nutrient partitioning and compromises behavioral and metabolic responses to leptin. FASEB 19 (2005) 1482-1491